B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model
暂无分享,去创建一个
S. Riddell | A. Heimberger | B. Séguin | P. Moore | S. Gottschalk | M. Jensen | A. Salter | S. Pollack | A. Zhang | B. Torok-Storb | Weiqing Jing | B. Alexiev | A. Koehne | Shihong Zhang | K. Abrams | Himaly Shinglot | Brian J Hayes | Karan Kohli | B. Schroeder | B. Schulte | C. Miller | R. G. Black | Brian C Schulte | Juliana Chi Kei Ng
[1] A. Davidoff,et al. A Novel Orthotopic Implantation Technique for Osteosarcoma Produces Spontaneous Metastases and Illustrates Dose-Dependent Efficacy of B7-H3-CAR T Cells , 2021, Frontiers in Immunology.
[2] Robin L. Jones,et al. IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy , 2021, Journal for ImmunoTherapy of Cancer.
[3] J. Rossmeisl,et al. Veterinary Cooperative Oncology Group—Common Terminology Criteria for Adverse Events (VCOG‐CTCAE v2) following investigational therapy in dogs and cats , 2021, Veterinary and comparative oncology.
[4] Lung-Ji Chang,et al. Canine osteosarcoma checkpoint expression correlates with metastasis and T-cell infiltrate. , 2020, Veterinary immunology and immunopathology.
[5] H. Heslop,et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma , 2020, Nature Communications.
[6] Shondra M. Pruett-Miller,et al. Route of 41BB/41BBL Costimulation Determines Effector Function of B7-H3-CAR.CD28ζ T Cells , 2020, Molecular therapy oncolytics.
[7] Derek W. Yecies,et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors , 2020, Nature Medicine.
[8] Meijia Yang,et al. B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors , 2020, Molecular therapy oncolytics.
[9] M. Atherton,et al. Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma , 2019, Oncoimmunology.
[10] N. Mason. Comparative Immunology and Immunotherapy of Canine Osteosarcoma. , 2020, Advances in experimental medicine and biology.
[11] Meijia Yang,et al. B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma , 2019, Molecular therapy oncolytics.
[12] Winnie S. Liang,et al. Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2 , 2019, Communications Biology.
[13] D. Maloney,et al. The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. , 2019, Blood.
[14] E. Moon,et al. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment , 2019, Front. Immunol..
[15] P. Sorensen,et al. CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors , 2019, Clinical Cancer Research.
[16] T. Blankenstein,et al. Effective NY-ESO-1–specific MHC II–restricted T cell receptors from antigen-negative hosts enhance tumor regression , 2018, The Journal of clinical investigation.
[17] J. Carpten,et al. Profiling targetable immune checkpoints in osteosarcoma , 2018, Oncoimmunology.
[18] Zev A. Binder,et al. Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas , 2018, Molecular therapy oncolytics.
[19] P. Dong,et al. B7H3 As a Promoter of Metastasis and Promising Therapeutic Target , 2018, Front. Oncol..
[20] Z. Mourelatos,et al. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model , 2017, Cancer Immunology Research.
[21] T. Mak,et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function , 2017, Cell Research.
[22] D. Busch,et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. , 2016, The Journal of clinical investigation.
[23] D. Powell,et al. Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma. , 2016, Molecular therapy : the journal of the American Society of Gene Therapy.
[24] Christine E Brown,et al. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. , 2016, Blood.
[25] K. Flaherty,et al. Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 , 2015, Journal of Immunotherapy for Cancer.
[26] C. Rooney,et al. Toward Immunotherapy With Redirected T Cells in a Large Animal Model: Ex Vivo Activation, Expansion, and Genetic Modification of Canine T Cells , 2014, Journal of immunotherapy.
[27] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[28] Hua Yu,et al. B7-H3 Associated with Tumor Progression and Epigenetic Regulatory Activity in Cutaneous Melanoma , 2013, The Journal of investigative dermatology.
[29] J. Dobson. Breed-Predispositions to Cancer in Pedigree Dogs , 2013, ISRN veterinary science.
[30] P. Moore,et al. Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity , 2012, Clinical Cancer Research.
[31] David L. Porter,et al. T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia , 2011, Science Translational Medicine.
[32] S. Riddell,et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. , 2011, Blood.
[33] R. Storb,et al. Antagonistic and Agonistic Anti-canine CD28 Monoclonal Antibodies: Tools for Allogeneic Transplantation , 2011, Transplantation.
[34] S. Rosenberg,et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.
[35] P. Meltzer,et al. Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression , 2009, BMC Genomics.
[36] M. Potter,et al. Functional impairment of human T-lymphocytes following PHA-induced expansion and retroviral transduction: implications for gene therapy , 2002, Gene Therapy.
[37] R. Storb,et al. Canine T cells transduced with a herpes simplex virus thymidine kinase gene: a model to study effects on engraftment and control of graft-versus-host disease. , 1998, Transplantation.